REGN


Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Reports 3Q:16 Financial and Operating Results

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced financial results for the third quarter of 2016 and provided a business update. “In the third quarter, we …

Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Receive Complete Response Letter from FDA for Sarilumab

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced the U.S.

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Provide Update on Fasinumab Clinical Development Programs

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical (NYSE:TEVA) provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced topline results from the Phase 2 CAPELLA study evaluating aflibercept co-formulated with rinucumab, an anti-platelet-derived growth factor receptor …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the U.S.

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) announced a globa agreement to develop and commercialize fasinumab, Regeneron’s investigational NGF antibody in …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Present Positive Phase 3 Investigational Data for Praluent at ESC Congress 2016

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in …

Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced an agreement with theBiomedical Advanced Research and Development Authority (BARDA) of the U.S.

This Analyst Cautious On Regeneron Pharmaceuticals Inc (REGN) Following 2Q:16 Results

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its second-quarter earnings results today, with U.S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts